Open Access
Organs-on-a-Chip Volume 3, November 2021, 100010
In vitro nonalcoholic fatty liver disease model with cyclo-olefin-polymer-based microphysiological systems
Xiaopeng Wen1, Koki Yoshimoto1,2,3, Makoto Yamanaka4, Shiho Terada1, Ken-ichiro Kamei1,5,6
1Institute for Integrated Cell-Material Sciences (WPI-iCeMS), Kyoto University, Yoshida-Ushinomiya-cho, Sakyo-ku, Kyoto, 606-8501, Japan
2Department of Biosystems Science, Institute for Frontier Life and Medical Sciences, Kyoto University, Shogoin-Kawara-cho, Sakyo-ku, Kyoto, 606-8397, Japan
3Laboratory of Cellular and Molecular Biomechanics, Graduate School of Biostudies, Kyoto University, Yoshida-Konoe-cho, Sakyo-ku, Kyoto, 606-8397, Japan
4Incubation Center Organs on Chip Project, Ushio INC, 1-6-5 Marunouchi, Chiyoda-ku, Tokyo, 100-8150, Japan
5Wuya College of Innovation, Shenyang Pharmaceutical University, Liaoning, 110016, People's Republic of China
6Department of Pharmaceutics, Shenyang Pharmaceutical University, Liaoning, 110016, People's Republic of China
In recent years, there has been a growing interest in using microfluidic chips called micro-physiological systems (MPS), which enable more detailed evaluation in in-vitro studies using cells. On the other hand, polydimethylsiloxane (PDMS), a silicone rubber-based material, is often used in developing MPS. However, PDMS absorbs hydrophobic molecules, which is a problem in applying several applications, such as non-alcoholic fatty liver disease (NAFLD) models in which free fatty acids (FFAs) are the causative agent. In this study, we employed chips made of cyclo-olefin polymer (COP) as a material that does not absorb FFAs, and developed and evaluated in vitro NAFLD model. Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases. Practical MPS will contribute to the development of new diagnostic and therapeutic agents.
For papers (You are leaving for an external site.)
Copyright © USHIO INC. All Rights Reserved.
